AI Article Synopsis
- Researchers studied BCR::ABL1 expression in 168 chronic myeloid leukemia patients who stopped treatment with imatinib or 2G-TKIs after achieving deep molecular response.
- Patients were categorized into two groups: those who maintained their response (group 1) and those who lost it (group 2), with group 2 showing significantly higher BCR::ABL1 RNA levels at both one and two months post-treatment.
- A threshold value of BCR::ABL1 at one month after stopping treatment was identified, with a cut-off value of 0.0051%, showing 92.2% specificity but only 31.7% sensitivity in predicting loss of major molecular response.
Article Abstract
We analyzed BCR::ABL1 expression at stop and in the first month after discontinuation in 168 chronic myeloid leukemia patients who stopped imatinib or 2nd generation tyrosine kinase inhibitors (2G-TKIs) while in sustained deep molecular response. Patients were divided among those who maintained response (group 1, n = 123) and those who lost major molecular response (group 2, n = 45). Mean BCR::ABL1 RNA levels 1 month after discontinuation were higher in group 2 than in group 1 (p = 0.0005) and the difference was more evident 2 months after stop (p < 0.0001). The same trend was found both for imatinib and 2G-TKIs. A receiver operating characteristic (ROC) analysis to determine a threshold value of BCR::ABL1 at 1 month after discontinuation identified a cut-off value of 0.0051%, with 92.2% specificity, 31.7% sensitivity and a likelihood ratio of 4.087.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939132 | PMC |
| http://dx.doi.org/10.1002/cam4.5158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!